FY2024 EPS Estimates for Zentalis Pharmaceuticals, Inc. Raised by Wedbush (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLFree Report) – Research analysts at Wedbush raised their FY2024 earnings estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Tuesday, June 18th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($2.31) per share for the year, up from their prior estimate of ($2.33). Wedbush currently has a “Underperform” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.78) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.02) EPS and FY2028 earnings at ($1.26) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.91. The business had revenue of $40.56 million during the quarter, compared to analyst estimates of $35.00 million. During the same period in the previous year, the company posted ($1.07) earnings per share.

Several other research firms also recently issued reports on ZNTL. Oppenheimer cut their price objective on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, June 18th. UBS Group cut shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $28.00 to $5.00 in a report on Thursday. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $29.00 to $9.00 in a report on Tuesday, June 18th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $6.00 price objective (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Stifel Nicolaus decreased their target price on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $11.33.

Check Out Our Latest Report on ZNTL

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $4.75 on Friday. The stock has a fifty day moving average of $10.99 and a 200-day moving average of $12.93. The company has a market capitalization of $337.39 million, a PE ratio of -1.43 and a beta of 1.83. Zentalis Pharmaceuticals has a one year low of $3.93 and a one year high of $29.63.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at $38,000. Tower Research Capital LLC TRC raised its position in shares of Zentalis Pharmaceuticals by 252.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the period. Exchange Traded Concepts LLC lifted its position in Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after acquiring an additional 1,519 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Zentalis Pharmaceuticals by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after purchasing an additional 6,379 shares during the last quarter. Finally, OneAscent Financial Services LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $156,000.

Insiders Place Their Bets

In related news, CFO Cam Gallagher sold 9,597 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the transaction, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at approximately $7,591,486.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the sale, the insider now owns 373,876 shares in the company, valued at $4,718,315.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Zentalis Pharmaceuticals Company Profile

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

See Also

Earnings History and Estimates for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.